Trevi Therapeutics (NASDAQ:TRVI) Shares Up 5.6% – Time to Buy?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) traded up 5.6% during trading on Tuesday . The stock traded as high as $18.87 and last traded at $18.9640. 929,713 shares changed hands during mid-day trading, a decline of 42% from the average session volume of 1,604,179 shares. The stock had previously closed at $17.95.

Analyst Ratings Changes

TRVI has been the topic of several recent analyst reports. D. Boral Capital restated a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a research report on Friday, April 17th. Stifel Nicolaus set a $30.00 price target on shares of Trevi Therapeutics in a research report on Friday, May 8th. Oppenheimer reissued an “outperform” rating on shares of Trevi Therapeutics in a research note on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Monday, April 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $22.67.

Trevi Therapeutics Stock Performance

The stock has a market capitalization of $2.78 billion, a PE ratio of -61.36 and a beta of 1.00. The company’s fifty day simple moving average is $15.13 and its two-hundred day simple moving average is $12.99.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Sell-side analysts forecast that Trevi Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. increased its position in Trevi Therapeutics by 194.5% during the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after buying an additional 2,996 shares in the last quarter. KBC Group NV purchased a new stake in shares of Trevi Therapeutics in the first quarter valued at $29,000. Hilton Head Capital Partners LLC acquired a new stake in shares of Trevi Therapeutics during the fourth quarter valued at $40,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Trevi Therapeutics during the fourth quarter valued at $50,000. Finally, Strs Ohio purchased a new stake in Trevi Therapeutics during the 1st quarter worth about $52,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.